Table 1.
Patient Characteristics and Outcomes, STEMI
| 2005–2007 | 2008–2010 | 2011–2013 | 2014–2015 | |
|---|---|---|---|---|
| Estimated number of visits | 1 402 768 | 1 192 090 | 694 494 | 315 813 |
| Demographic characteristics, N (%) | ||||
| Age, y, mean (SE) | 64.9 (1.2) | 63.5 (1.1) | 65.1 (1.7) | 68.2 (2.4) |
| Male | 797 965 (56.9) | 681 363 (57.2) | 436 145 (62.8) | 149 949 (47.5) |
| White | 1 121 066 (79.9) | 890 081 (74.7) | 523 509 (75.4) | 279 486 (88.5) |
| Black | 164 334 (11.7) | 116 696 (9.8) | 99 578 (14.3) | 20 819 (6.6) |
| Hispanic | 84 801 (6.1) | 135 981 (11.4) | 61 149 (8.8) | 15 508 (4.9) |
| Other race | 32 567 (2.3) | 49 332 (4.1) | 10 258 (1.5) | 0 (0.0) |
| Outcomes, % (SE) | ||||
| ED LOS, median (IQR), min | 195 (121, 315) | 211 (83, 325) | 158 (70, 296) | 148 (59, 220) |
| Admitted | 66.3 (3.3) | 72.2 (3.9) | 68.9 (4.9) | 57.6 (8.1) |
| Admission to critical care unit | 34.0 (4.1) | 33.6 (4.5) | 31.9 (5.9) | 39.6 (9.8) |
| Admission to cardiac catheterization lab | 11.8 (2.7) | 23.4 (4.5) | 36.7 (7.1) | 37.3 (8.5) |
| Transferred | 19.7 (3.0) | 14.9 (3.1) | 20.9 (4.4) | 24.4 (6.8) |
| Nonaspirin antiplatelet agents | 10.5 (2.0) | 13.6 (2.7) | 13.1 (2.9) | 26.6 (8.3) |
| Intravenous antithrombotic agents | 23.0 (2.5) | 28.7 (3.8) | 30.2 (4.8) | 30.7 (7.6) |
| Fibrinolytic agents | 2.2 (1.1) | 1.8 (1.4) | 3.8 (1.7) | 5.0 (3.0) |
| Glycoprotein IIb/IIIa inhibitors | 5.0 (1.2) | 3.6 (1.5) | 3.3 (1.9) | 5.8 (3.4) |
ED indicates emergency department; IQR, interquartile range; LOS, length of stay; and STEMI, ST‐segment–elevation myocardial infarction.